Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Leukemia

  Free Subscription


Articles published in Proc Natl Acad Sci U S A

Retrieve available abstracts of 22 articles:
HTML format
Text format



Single Articles


    September 2017
  1. RASSENTI LZ, Balatti V, Ghia EM, Palamarchuk A, et al
    MicroRNA dysregulation to identify therapeutic target combinations for chronic lymphocytic leukemia.
    Proc Natl Acad Sci U S A. 2017 Sep 18. pii: 201708264.
    PubMed     Text format     Abstract available


    May 2017
  2. PAPAIOANNOU D, Shen C, Nicolet D, McNeil B, et al
    Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia.
    Proc Natl Acad Sci U S A. 2017 May 22. pii: 201703142.
    PubMed     Text format     Abstract available


  3. DAI YJ, Wang YY, Huang JY, Xia L, et al
    Conditional knockin of Dnmt3a R878H initiates acute myeloid leukemia with mTOR pathway involvement.
    Proc Natl Acad Sci U S A. 2017 May 1. pii: 201703476.
    PubMed     Text format     Abstract available


  4. SCHWARTZMAN O, Savino AM, Gombert M, Palmi C, et al
    Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome.
    Proc Natl Acad Sci U S A. 2017 May 1. pii: 201702489.
    PubMed     Text format     Abstract available


    March 2017
  5. FABBRI G, Holmes AB, Viganotti M, Scuoppo C, et al
    Common nonmutational NOTCH1 activation in chronic lymphocytic leukemia.
    Proc Natl Acad Sci U S A. 2017 Mar 17. pii: 201702564.
    PubMed     Text format     Abstract available


    February 2017
  6. SJOBERG M, Loving R, Lindqvist B, Garoff H, et al
    Sequential activation of the three protomers in the Moloney murine leukemia virus Env.
    Proc Natl Acad Sci U S A. 2017 Feb 21. pii: 201617264.
    PubMed     Text format     Abstract available


    October 2016
  7. GREGORY MA, D'Alessandro A, Alvarez-Calderon F, Kim J, et al
    ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia.
    Proc Natl Acad Sci U S A. 2016;113:E6669-E6678.
    PubMed     Text format     Abstract available


    September 2016
  8. LU SX, Abdel-Wahab O
    Genetic drivers of vulnerability and resistance in relapsed acute lymphoblastic leukemia.
    Proc Natl Acad Sci U S A. 2016 Sep 23. pii: 201613836.
    PubMed     Text format    


  9. OSHIMA K, Khiabanian H, da Silva-Almeida AC, Tzoneva G, et al
    Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia.
    Proc Natl Acad Sci U S A. 2016 Sep 21. pii: 201608420.
    PubMed     Text format     Abstract available


    May 2016
  10. YEH CH, Bellon M, Pancewicz-Wojtkiewicz J, Nicot C, et al
    Oncogenic mutations in the FBXW7 gene of adult T-cell leukemia patients.
    Proc Natl Acad Sci U S A. 2016 May 31. pii: 201601537.
    PubMed     Text format     Abstract available


  11. VOLPON L, Culjkovic-Kraljacic B, Osborne MJ, Ramteke A, et al
    Importin 8 mediates m7G cap-sensitive nuclear import of the eukaryotic translation initiation factor eIF4E.
    Proc Natl Acad Sci U S A. 2016;113:5263-8.
    PubMed     Text format     Abstract available


  12. PEKARSKY Y, Balatti V, Palamarchuk A, Rizzotto L, et al
    Dysregulation of a family of short noncoding RNAs, tsRNAs, in human cancer.
    Proc Natl Acad Sci U S A. 2016;113:5071-6.
    PubMed     Text format     Abstract available


    March 2016
  13. KIM W, Le TM, Wei L, Poddar S, et al
    [18F]CFA as a clinically translatable probe for PET imaging of deoxycytidine kinase activity.
    Proc Natl Acad Sci U S A. 2016 Mar 28. pii: 201524212.
    PubMed     Text format     Abstract available


    February 2016
  14. TRIPLETT TA, Cardenas KT, Lancaster JN, Hu Z, et al
    Endogenous dendritic cells from the tumor microenvironment support T-ALL growth via IGF1R activation.
    Proc Natl Acad Sci U S A. 2016;113:E1016-25.
    PubMed     Text format     Abstract available


  15. HAO Z, Cairns RA, Inoue S, Li WY, et al
    Idh1 mutations contribute to the development of T-cell malignancies in genetically engineered mice.
    Proc Natl Acad Sci U S A. 2016;113:1387-92.
    PubMed     Text format     Abstract available


    January 2016
  16. RODGERS DT, Mazagova M, Hampton EN, Cao Y, et al
    Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies.
    Proc Natl Acad Sci U S A. 2016;113:E459-68.
    PubMed     Text format     Abstract available


  17. MA JS, Kim JY, Kazane SA, Choi SH, et al
    Versatile strategy for controlling the specificity and activity of engineered T cells.
    Proc Natl Acad Sci U S A. 2016;113:E450-8.
    PubMed     Text format     Abstract available


  18. ROZHOK AI, Salstrom JL, DeGregori J
    Stochastic modeling reveals an evolutionary mechanism underlying elevated rates of childhood leukemia.
    Proc Natl Acad Sci U S A. 2016 Jan 11. pii: 201509333.
    PubMed     Text format     Abstract available


    December 2015
  19. COFFIN JM
    The discovery of HTLV-1, the first pathogenic human retrovirus.
    Proc Natl Acad Sci U S A. 2015;112:15525-9.
    PubMed     Text format     Abstract available


    November 2015
  20. HOLM F, Hellqvist E, Mason CN, Ali SA, et al
    Reversion to an embryonic alternative splicing program enhances leukemia stem cell self-renewal.
    Proc Natl Acad Sci U S A. 2015 Nov 30. pii: 201506943.
    PubMed     Text format     Abstract available


  21. YEA K, Zhang H, Xie J, Jones TM, et al
    Agonist antibody that induces human malignant cells to kill one another.
    Proc Natl Acad Sci U S A. 2015;112:E6158-65.
    PubMed     Text format     Abstract available


    September 2015
  22. LOVAT F, Fassan M, Gasparini P, Rizzotto L, et al
    miR-15b/16-2 deletion promotes B-cell malignancies.
    Proc Natl Acad Sci U S A. 2015;112:11636-41.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: